Navigation Links
Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages
Date:12/6/2009

tach from its point of origin and travel through the heart to the lungs, causing a potentially fatal condition known as a pulmonary embolism.

Currently, patients with VTE are treated with a blood thinner known as warfarin, which has many burdensome interactions with other medications and foods and requires frequent monitoring of the dosage. However, this study shows that an oral drug called dabigatran etexilate, which does not have these disadvantages, is as safe and effective as warfarin for combating VTE.

To compare the two drugs, an international team of researchers conducted a randomized, double-blind trial of 2,539 patients with acute VTE. For six months, roughly half of the patients in the trial (1,274) were given a fixed dose of 150 mg of dabigatran etexilate twice daily, while the other half (1,265 patients) were given warfarin once daily in doses adjusted to an International Normalized Ratio (INR) of 2.0 to 3.0. INR is a blood test needed to monitor the effects of warfarin therapy to ensure an adequate, yet safe, dose is taken; in this study, the test was performed, on average, every 11 days.

The improvement seen in both groups from the treatments was similar. After six months of treatment, only 2.4 percent of the dabigatran etexilate group (30 patients) and 2.2 percent of the warfarin group (27 patients) experienced recurrent VTE. The safety of the two drugs was also comparable. In the dabigatran etexilate arm, 207 patients experienced bleeding (including 20 patients with major bleeding) versus 280 patients in the warfarin arm (including 24 with major bleeding). Other possible side effects, including death, acute coronary syndromes, and abnormalities in liver function tests, were infrequent in the two groups.

"We are excited by these findings and feel that they will change the standard of care for venous thromboembolism, which affects a large number of our patients," said lead study author Sam Schulman, MD, Prof
'/>"/>

SOURCE American Society of Hematology
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. The Ensign Group Acquires Three Texas Skilled Nursing Facilities
2. Three-Month Supply Lowers Drug Costs
3. BioConference Live Kicks-off Three Day Online Event for Life Science and Biotech Communities Today at 9:00 AM Eastern
4. Compirion Healthcare Solutions Wins Consulting Contracts With Three Hospitals
5. Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds
6. PEER 1 UK Signs 100 Business Hosting Customers in Three Months
7. Endologix to Present at Three Upcoming Conferences
8. Patrick Soon-Shiong, MD, and Three Healthcare Companies Win 2009 Innovations in Healthcare Awards
9. Circadiance Launches NEW Zzzephyr Seal(TM) for Its SleepWeaver(TM) ADVANCE Mask - Now Available in Three Colors
10. CDPHP Launches National Network and Three-In-One Plan, and Expands Member Incentives
11. Blue Cross Names Three New Executives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... ... , ... Next weekend is Labor Day weekend, the last bash of the ... this year). For IT security personnel, it should also mark the perfect time to ... costly than a simple headache. , Joe Caruso, founder and CEO-CTO of Global ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences announced today ... and Arterosil HP, and that all claims and counterclaims have been irrevocably dismissed. ... (VHS) in the United States District Court for the Southern District of Texas ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner ... they are applying for, they are unable to pass the initial drug test and ... testing policies in order to be able to hire long-term, skilled talent. (1) Will ...
(Date:8/28/2015)... Baltimore, MD (PRWEB) , ... August 28, 2015 , ... ... reduction system from Merz, received FDA clearance for results that last for two ... clearance is exciting news for patients who are looking for a long-lasting, effective solution ...
(Date:8/28/2015)... ... 28, 2015 , ... “ Frequentz ” was featured on NewsWatch as part ... on the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch ... allows businesses to track product movement from beginning to end. , Businesses benefit greatly ...
Breaking Medicine News(10 mins):Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Track Product Movement from Beginning to End with Frequentz 2
... the new central clearing house for an ambitious ongoing ... of biomedical data to make it more accessible to ... Resources, a component institute of the National Institutes of ... support the Biomedical Informatics Research Network Coordinating Center (BIRNCC) ...
... offer hope of better hearing for people who suffer ... the non-profit educational organization Better Hearing Institute (BHI). The ... States and Canada found that six out of ten ... hearing aids and two of ten reported major relief. ...
... for surrogates enrolling loved ones in research studies , , ... support having their family members enroll them in disease ... decision themselves, a new study says. , ... would prove especially helpful in studying people with Alzheimer,s ...
... Jan. 21 Health Integrated, a pioneer in targeted ... has joined the fast-growing company as Senior Vice President ... Health Integrated,s Solutions Group which will extend on the ... customers, their members, and network of providers. "Vic is ...
... between tobacco smoke and cancer deaths beyond lung ... study from a UC Davis researcher, suggesting that increased ... estimated. , The epidemiological analysis, published online in ... percent of the cancer death burden among Massachusetts men ...
... 21 Nu Skin Enterprises, Inc. (NYSE: NUS ... year-end 2008 financial results prior to the market opening on ... will host a conference call with the investment community later ... the call, participants can expect to hear management review past ...
Cached Medicine News:Health News:USC awarded $22.2M NIH national biomedical informatics infrastructure coordinating center contract 2Health News:Hearing Aids Offer Hope for Those Who Suffer from Persistent 'Ringing in the Ears,' Better Hearing Institute Survey Finds 2Health News:Hearing Aids Offer Hope for Those Who Suffer from Persistent 'Ringing in the Ears,' Better Hearing Institute Survey Finds 3Health News:Hearing Aids Offer Hope for Those Who Suffer from Persistent 'Ringing in the Ears,' Better Hearing Institute Survey Finds 4Health News:Decide for Me When I Can't, Most People Say 2Health News:Victor Dragon Joins Health Integrated to Lead Solutions Group 2Health News:UC Davis study links smoking with most male cancer deaths 2
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
(Date:8/28/2015)... , FARUM, Denmark and ... On July 31, 2015 the US Food and Drug ... treatment of Major Depressive Disorder in adult patients who have ... the current episode. TMS is a non-invasive technique for stimulating ... patients suffering from Major Depressive Disorder. The procedure has been ...
(Date:8/28/2015)... , Aug. 28, 2015 ... and Dr. Ra from Biostar , Published in ... 30% increase of lifespan through multiple IV administration of ... vitality, and life expectancy found , Commercialization within ... have determined the possibility that adult mesenchymal stem cells ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
... Therapeutics,(OTC Bulletin Board: ECTE) today announced positive ... Transdermal Continuous Glucose Monitoring (tCGM),System in patients ... Echo,s non-invasive,Symphony tCGM System consists of its ... Prelude(TM) SkinPrep System, which,incorporates leading-edge, needle-free skin ...
... TRIANGLE PARK, N.C., July 27 Timothy Mastro,MD, ... on August 1st,as Senior Director of Research, will ... for HIV prevention at the,International AIDS Conference in ... Prophylaxis: Current,and Planned Trials," will examine ongoing and ...
Cached Medicine Technology:Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 2Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 3Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 4HIV Prevention Expert Dr. Timothy Mastro Speaks on Future of Pre-Exposure Prophylaxis at International AIDS Conference 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: